Drugs News and Research

RSS

Drug-loaded plaster delivers active agent to premature babies via membrane

The development of minimally and even non-invasive technologies is increasing in the medical field. It is now possible, for instance, to carry out a range of operative procedures using keyhole surgery with minimal use of the scalpel, leaving only tiny scars as a result. Similar opportunities are now becoming available when providing doses of active agents to patients – instead of using injections or probes to deliver drugs, it will in future be possible to supply them via a plaster which continuously, gently and painlessly delivers the required dosage through the skin.

30 Oct 2014

Mediterranean-style diets, physical activity can lower risk of first-time stroke

Eating Mediterranean or DASH-style diets, regularly engaging in physical activity and keeping your blood pressure under control can lower your risk of a first-time stroke, according to updated AHA/ASA guideline published in the American Heart Association's journal Stroke.

30 Oct 2014

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

30 Oct 2014

Major research project aims to reduce chances of hair loss after chemotherapy treatment

Cancer suffers who lose their hair as a consequence of chemotherapy will benefit from a major research project that will improve the scalp cooling technology that prevents hair loss.

From Paxman 30 Oct 2014

UBC researchers set to develop universal antidote to simplify use of heparin

Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by developing a universal antidote.

29 Oct 2014

Genetic differences contribute to risk for autism

Small differences in as many as a thousand genes contribute to risk for autism, according to a study led by Mount Sinai researchers and the Autism Sequencing Consortium, and published today in the journal Nature.

29 Oct 2014

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

The uncontrolled growth of cancer cells arises from their ability to hijack the cell’s normal growth program and checkpoints. Usually after therapy, a second cancer-signaling pathway will open after the primary one shuts down — creating an ingenious escape route for the cancer cell to survive. The answer, say Case Western Reserve researchers, is to anticipate and block that back-up track by prescribing two drugs from the start.

29 Oct 2014

TSRI scientists discover signaling pathway that contribute to Huntington's disease

Scientists from the Florida campus of The Scripps Research Institute have uncovered a major contributor to Huntington's disease, a devastating progressive neurological condition that produces involuntary movements, emotional disturbance and cognitive impairment.

29 Oct 2014

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other.

29 Oct 2014

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.

28 Oct 2014

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis.

28 Oct 2014

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Recent breakthroughs may pave the way for vaccines and new drugs for those infected by parasitic helminths. These flatworms, including tapeworms that cause hydatid diseases and neurocysticercosis, liver flukes, and blood flukes (schistosomes), infect more than 300 million people and cause approximately four million disability-adjusted life years lost due to chronic illness and death each year.

28 Oct 2014

New model of primary care could improve health of patients with type 2 diabetes

A new model of delivering primary care studied by Keck Medicine of the University of Southern California researchers has the potential to improve the health of patients with type 2 diabetes.

28 Oct 2014

ETEC vaccine candidate provides significant protection against bacterial diarrhea

New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease.

28 Oct 2014

Study finds that mental health disorders double heart disease, stroke risks

People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress.

28 Oct 2014

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.

28 Oct 2014

New research suggests that TEM5 protein may be a good target for cancer therapy

Do blood vessels that feed tumors differ from other blood vessels? Fourteen years ago, experiments designed to answer that question led to the discovery of several genes that are more active in tumor-associated blood vessels than in normal blood vessels. New research now reveals the normal function of one of those genes and suggests it could be a good target for anticancer drug therapy.

28 Oct 2014

Researchers receive EPSRC grant to develop real-time diagnostic technique for dementia

A research team from Plymouth University, together with colleagues from Swansea University, has received funding of £1M from the Engineering and Physical Sciences Research Council to develop an innovative, real-time diagnostic technique for dementia using wonder-material graphene.

27 Oct 2014

RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

Scientists say they have identified in about 20 percent of colorectal and endometrial cancers a genetic mutation that had been overlooked in recent large, comprehensive gene searches. With this discovery, the altered gene, called RNF43, now ranks as one of the most common mutations in the two cancer types.

27 Oct 2014

MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies worldwide.

27 Oct 2014

Drugs News and Research

Drug-loaded plaster delivers active agent to premature babies via membrane

Mediterranean-style diets, physical activity can lower risk of first-time stroke

Study: Certain prostate cancer medications linked to cardiac death risk

Major research project aims to reduce chances of hair loss after chemotherapy treatment

UBC researchers set to develop universal antidote to simplify use of heparin

Genetic differences contribute to risk for autism

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

TSRI scientists discover signaling pathway that contribute to Huntington's disease

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

New model of primary care could improve health of patients with type 2 diabetes

ETEC vaccine candidate provides significant protection against bacterial diarrhea

Study finds that mental health disorders double heart disease, stroke risks

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

New research suggests that TEM5 protein may be a good target for cancer therapy

Researchers receive EPSRC grant to develop real-time diagnostic technique for dementia

RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

MPI Research announces acquisition of Jasper Clinical Research & Development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News